China SXT Pharmaceuticals (NASDAQ:SXTC) Shares Down 3.7% – Here’s What Happened

Posted by ABMN Staff on Dec 23rd, 2025

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC – Get Free Report) traded down 3.7% during trading on Monday . The stock traded as low as $1.54 and last traded at $1.55. 12,379 shares changed hands during mid-day trading, a decline of 91% from the average session volume of 137,917 shares. The stock had previously closed at $1.61.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of China SXT Pharmaceuticals in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Read Our Latest Stock Analysis on China SXT Pharmaceuticals

China SXT Pharmaceuticals Trading Down 3.7%

The stock’s 50-day moving average is $1.41 and its 200-day moving average is $1.59. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.40 and a current ratio of 3.54.

Institutional Trading of China SXT Pharmaceuticals

A hedge fund recently raised its stake in China SXT Pharmaceuticals stock. Virtu Financial LLC lifted its stake in shares of China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC – Free Report) by 107.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,983 shares of the company’s stock after acquiring an additional 15,013 shares during the period. Virtu Financial LLC’s holdings in China SXT Pharmaceuticals were worth $46,000 as of its most recent SEC filing. Institutional investors and hedge funds own 5.02% of the company’s stock.

China SXT Pharmaceuticals Company Profile

(Get Free Report)

China SXT Pharmaceuticals Inc (NASDAQ: SXTC) is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.